The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

The company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Sarepta Therapeutics Inc. shares soared after the company said it was cutting more than a third of its workforce and that its ...

The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene ...

Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...

Sarepta Therapeutics Inc. said another patient has died from acute liver failure after receiving one of its gene therapies, putting additional pressure on the biotech company after the recent deaths ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

After the market close on Wednesday, Sarepta Therapeutics introduced a strategic restructuring plan that involves focusing on high-value, high-impact programs and supporting long-term financials.

TSMC shares rose 4% in premarket trade as the contract chip manufacturer lifted its 2025 sales guidance. Sarepta Therapeutics stock jumped 34% as the company set plans to lay off more than a third of ...

The company will also add a warning label to its gene therapy Elevidys after the deaths of two teenage patients this year.

At the FDA's request, delandistrogene moxeparvovec (Elevidys), the only approved gene therapy for Duchenne muscular dystrophy ...